Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey
Sign Up to like & getrecommendations! Published in 2020 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.24854
Abstract: A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor‐ivacaftor, tezacaftor‐ivacaftor, and elexacaftor‐tezacaftor‐ivacaftor. This cross‐sectional study evaluated cystic fibrosis (CF) patients eligible for… read more here.
Keywords: cystic fibrosis; eligible modulator; patients eligible; modulator drugs ... See more keywords
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16030410
Abstract: Cystic fibrosis (CF) is a potentially fatal monogenic disease that causes a progressive multisystemic pathology. Over the last decade, the introduction of CF transmembrane conductance regulator (CFTR) modulator drugs into clinical practice has profoundly modified… read more here.
Keywords: modulator drugs; cftr; ivacaftor; cftr modulator ... See more keywords